Molecular structure of AGL 2043, CAS Number: 22617-28-8
AGL 2043 (CAS 22617-28-8)
Application:
AGL 2043 is a cell permeable compound that acts as a potent inhibitor of type III receptor tyrosine kinases
CAS Number:
22617-28-8
Molecular Weight:
280.4
Molecular Formula:
C15H12N4S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
AGL 2043 is a cell-permeable, tricyclic quinoxaline compound that acts as a potent, selective, ATP-competitive, and reversible inhibitor of type III receptor tyrosine kinases, PDGFR (IC50 = 800 nM in 3T3 cells; 90 nM against purified PDGFβ-receptor), Flt3, and Kit (IC50 ~1-3 µM). Weakly inhibits PKA, EGFR, IGF-1R, VEGFR, and Src kinases (IC50 > 30 µM). Potently inhibits smooth muscle cell proliferation and balloon-induced stenosis in porcine heart.
AGL 2043 (CAS 22617-28-8) References
- Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. | Gazit, A., et al. 2003. Bioorg Med Chem. 11: 2007-18. PMID: 12670652
- Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. | Banai, S., et al. 2005. Biomaterials. 26: 451-61. PMID: 15275819
- Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. | Banai, S., et al. 2004. Cardiovasc Res. 64: 165-71. PMID: 15364624
- Microwave-assisted and traceless synthesis of imidazoquinoxalinones. | Lin, MJ. and Sun, CM. 2006. J Comb Chem. 8: 455-8. PMID: 16827554
- Delivery of large biopharmaceuticals from cardiovascular stents: a review. | Takahashi, H., et al. 2007. Biomacromolecules. 8: 3281-93. PMID: 17929968
- Stent-based release of a selective PDGF-receptor blocker from the bis-indolylmethanon class inhibits restenosis in the rabbit animal model. | Jandt, E., et al. 2010. Vascul Pharmacol. 52: 55-62. PMID: 19951743
- Imatinib mesylate-incorporated nanoparticle-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries. | Masuda, S., et al. 2011. J Atheroscler Thromb. 18: 1043-53. PMID: 21996703
- MuLV-related endogenous retroviral elements and Flt3 participate in aberrant end-joining events that promote B-cell leukemogenesis. | Johnson, RM., et al. 2014. Genes Dev. 28: 1179-90. PMID: 24888589
- Recent advances in micro/nanoscale biomedical implants. | Arsiwala, A., et al. 2014. J Control Release. 189: 25-45. PMID: 24960225
- Nanocarriers for the Delivery of Quercetin to Inhibit the UV-Induced Aggregation of γD-Crystallin. | Goswami, V., et al. 2024. Langmuir. 40: 5617-5631. PMID: 38051761
Inhibitor of:
c-Kit, Enzyme, Flt-3/Flk-2, PDGFR-beta, and Tyrosine Kinase.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AGL 2043, 1 mg | sc-203808 | 1 mg | $295.00 |